Press Releases

Announces hiring of Patrick Verta, MD, as Executive VP of Clinical and Medical Affairs Cheryl Tal joins as VP of Quality Assurance and Regulatory Affairs Shane Gleason, current General Manager of North America & VP of Global Marketing, promoted to Chief Commercial Officer Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Tel Aviv, Israel, and… Read More

Tel Aviv, Israel, and Miami, Florida — August 31, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract detailing upcoming 30-day results from its C-Guardians U.S. IDE clinical trial has been accepted for presentation as a late-breaking clinical trial… Read More

– Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – – Completed enrollment in the C-Guardians US IDE trial; on track to announce primary and secondary endpoints and, if successful, submit PMA application in H2 2024 – – Generated Q2 2023 CGuard EPS revenue of $1.6 million, an increase of… Read More

Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system Study also included first-in-human cases treated with CGuard Prime CAS stent delivery platform  Company anticipates study results and Premarket Approval (PMA) submission in H2 2024, potential U.S. approval in H1 2025 Tel Aviv, Israel — June 26, 2023 – InspireMD,… Read More

Tel Aviv, Israel and Miami, Florida — May 18, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that, in connection with the appointment of Shane Gleason as General Manager of North America and VP of Global Marketing in February 2023, InspireMD… Read More

– Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – – Generated Q1 2023 CGuard EPS revenue of $1.2 million, an increase of 6.7% over Q1 2022 despite the temporary expiration of the Company’s CE Mark certification until mid-March – – Resumed shipments of CGuard EPS to CE Mark territories… Read More

Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members   $42.2 million financing upfront with up to an additional $71.4 million tied to exercise of milestone-driven warrants   Tel Aviv, Israel and Miami, Florida — May 15, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS)… Read More

  -Conference call and webcast to be held at 8:30 a.m. EDT-  Tel Aviv, Israel— May 12, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today that it will host its conference call and webcast to… Read More

  -Conference call and webcast to be held at 8:30 a.m. EDT-   Tel Aviv, Israel— May 5, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will now report first quarter 2023 financial results… Read More

  Procedure performed as part of the company’s ongoing CGuardians U.S. Investigational Device Exemption (IDE) trial designed to support potential U.S. marketing approval of the CGuard stent system. CGuardians enrollment on track to be completed by the end of Q2 2023   Tel Aviv, Israel — May 1, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of… Read More